Barclays’s Plus Therapeutics PSTV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Hold
0
5347
2025
Q4
Hold
0
5192
2025
Q3
Sell
-4
Closed -$49 5451
2025
Q2
$36 Sell
4
-38
-90% -$497 ﹤0.01% 5130
2025
Q1
$987 Buy
+42
New +$1.17K ﹤0.01% 5051
2023
Q2
Hold
0
4976
2023
Q1
Hold
0
5293
2022
Q4
Hold
0
5351
2022
Q3
Hold
0
5060
2022
Q2
Hold
0
5208
2022
Q1
Hold
0
5477
2019
Q3
Hold
0
7043
2019
Q2
Hold
0
7196
2019
Q1
Sell
-5
Closed -$26.4K 7258
2018
Q4
$29K Buy
5
+4
+400% +$26.3K ﹤0.01% 5743
2018
Q3
$5K Buy
+1
New +$12.7K ﹤0.01% 6794
2018
Q2
Hold
0
7217
2018
Q1
Hold
0
7269
2017
Q4
Hold
0
7067
2017
Q3
Hold
0
6765
2017
Q2
Hold
0
6438
2017
Q1
Hold
0
6491
2016
Q4
Hold
0
6365
2016
Q3
Hold
0
6152
2016
Q2
Hold
0
5867
2016
Q1
Hold
0
6378
2015
Q4
Hold
0
6458
2015
Q3
Hold
0
6998
2015
Q2
Hold
0
7162
2015
Q1
Hold
0
6771
2014
Q4
Hold
0
7531
2014
Q3
Hold
0
7791
2014
Q2
Hold
0
7406
2014
Q1
Hold
0
7030
2013
Q4
Hold
0
6598
2013
Q3
Hold
0
6900
2013
Q2
Hold
0
6687

Other funds holding PSTV

Barclays's PSTV Position: Q1 2026 in Review

Barclays held its Plus Therapeutics (PSTV) position steady in Q1 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5347.

Barclays first reported a position in PSTV in Q3 2018 and has held it in 4 quarters since. The position peaked at $29K in Q4 2018. 23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

  • Barclays held 0 shares of Plus Therapeutics worth $0 as of Q1 2026.
  • Barclays left its Plus Therapeutics share count unchanged in Q1 2026.
  • Plus Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #5347 holding.
  • Barclays first reported a position in Plus Therapeutics in Q3 2018 and has held it in 4 quarters since.
  • Barclays's Plus Therapeutics position peaked at $29K in Q4 2018.
  • 23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.